BlackRock’s Bright Minds Biosciences DRUG Stock Holding History

BlackRock’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$45.4M	Buy	621,933 +227,890	+58%	+$18.3M	﹤0.01%	2570
2025 Q4	$30.8M	Buy	394,043 +159,925	+68%	+$10.7M	﹤0.01%	2823
2025 Q3	$14.2M	Buy	234,118 +24,441	+12%	+$949K	﹤0.01%	3273
2025 Q2	$5.47M	Buy	209,677 +208,999	+30,826%	+$6.27M	﹤0.01%	3730
2025 Q1	$24.5K	Buy	678 +677	+67,700%	+$24.8K	﹤0.01%	5062
2024 Q4	$36	Hold	1	–	–	﹤0.01%	5364
2024 Q3	$1	Hold	1	–	–	﹤0.01%	5220
2024 Q2	$1	Hold	1	–	–	﹤0.01%	5275
2024 Q1	$1	Hold	1	–	–	﹤0.01%	5279
2023 Q4	$1	Hold	1	–	–	﹤0.01%	5371
2023 Q3	$2	Sell	1 -2,359	-100%	-$6.29K	﹤0.01%	5442
2023 Q2	$6.73K	Hold	2,360	–	–	﹤0.01%	5284
2023 Q1	$5.19K	Hold	2,360	–	–	﹤0.01%	5368
2022 Q4	$8.73K	Hold	2,360	–	–	﹤0.01%	5480
2022 Q3	$15K	Hold	2,360	–	–	﹤0.01%	5550
2022 Q2	$9K	Hold	2,360	–	–	﹤0.01%	5636
2022 Q1	$18K	Buy	2,360 +1,126	+91%	+$12.6K	﹤0.01%	5577
2021 Q4	$20K	Buy	+1,234	New	+$27.5K	﹤0.01%	5538

Other funds holding DRUG

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock's DRUG Position: Q1 2026 in Review

BlackRock increased its Bright Minds Biosciences (DRUG) stake by 58% in Q1 2026, buying an estimated $18.3M and bringing the position to 621,933 shares worth $45.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2570.

BlackRock first reported a position in DRUG in Q4 2021 and has held it in 18 quarters since. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

BlackRock held 621,933 shares of Bright Minds Biosciences worth $45.4M as of Q1 2026.
BlackRock bought 227,890 Bright Minds Biosciences shares in Q1 2026, an estimated $18.3M.
Bright Minds Biosciences made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2570 holding.
BlackRock first reported a position in Bright Minds Biosciences in Q4 2021 and has held it in 18 quarters since.
94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.